Allosteris
Financiado
Allosteric modulation of immune checkpoint complexes as a new mode of therapeuti...
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapy
The fastidious balance of our immune system to fight infections or cancer while avoiding autoimmune reactions is regulated by coinhibitory and co-stimulatory immune checkpoint complexes (ICCs), which have become major drug targets...
The fastidious balance of our immune system to fight infections or cancer while avoiding autoimmune reactions is regulated by coinhibitory and co-stimulatory immune checkpoint complexes (ICCs), which have become major drug targets. We witness the skyrocketing progression in cancer immunotherapy with antibodies that block inhibitory ICCs whereas Abs that block stimulatory ICCs are in clinical trials for treating autoimmune diseases.
Surprisingly, but likely fuelled by the most obvious focus on IC inhibitors, the field largely ignored that ICCs are genuine transmembrane receptors that transmit signals upon binding of an extracellular protein ligand. This leaves unexplored modes of therapeutic intervention that I will uncover by validating Nanobodies (Nbs) as first-in-class modulators of signaling pathways associated with immune receptors in a unique, previously unexplored fashion.
By applying innovative immunization and bio-selection techniques and building on POC data, I will deliver Nbs for representative ICCs to demonstrate the efficacy and selectivity of these Nbs in preclinical models of various inflammatory conditions, focusing on cancer and autoimmune diseases. We will deliver novel therapeutics agents which may outperform current inhibitor-based immunotherapies that trigger a magnitude of side effects. In this regard, the Nbs will exert their therapeutic effect through a distinctive mode of action that will ensure patient safety, even in the event of an overdose.
ver más
Duración del proyecto: 60 meses
Fecha Inicio: 2024-05-22
Fecha Fin: 2029-05-31
Fecha Fin: 2029-05-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-22
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2023-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
VIB VZW
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5